(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead says Trodelvy with Merck’s Keytruda controls lung cancer Sep. 10, 2023 5:30 AM ET Gilead Sciences, Inc. (GILD) Stock, MRK Stock By: Dulan Lokuwithana, SA News Editor 11 Comments ...

Gilead’s Trodelvy — an antibody-drug conjugate, the new line of more targeted chemotherapy — was combined with Merck’s immunotherapy Keytruda as an initial treatment for triple-negative ...

Gilead Sciences, Inc. today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy ® in combination with Merck’ s anti-PD-1 therapy KEYTRUDA ...

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm.

In October 2021, Gilead and Merck collaborated to evaluate Trodelvy in combination with Keytruda as a first-line treatment for patients with locally advanced or metastatic TNBC.

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Gilead and Merck collaborated in 2021 to evaluate Trodelvy in combination with Keytruda in the phase III ASCENT-04/KEYNOTE-D19 study. Shares of GILD have gained 20% year to date against the ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...